Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hetero Set To Join Indian Humira Biosimilar Line-Up

Executive Summary

Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.

You may also be interested in...



Boehringer Ingelheim Limbering Up With Humira Biosimilar

Presenting equivalence data at EULAR for its biosimilar version of the world's best-selling drug, Humira, Boehringer Ingelheim is optimistic about its position in a crowded field. Karsten Kissel, head of global medical affairs biosimilars for the German group, spoke to Scrip.

India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?

India plans pivotal tweaks to its three-layered review process for clinical trial-related clearances – a move that is expected to pare approval timelines significantly and improve predictability for sponsors who have been generally cautious, over the recent past, about placing studies in the country.

Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch

Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel